Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Malaysia Genome and Vaccine Institute (MGVI) is a premier research organization under the National Institutes of Biotechnology Malaysia (NIBM). Operating as a non-profit Company Limited by Guarantee, MGVI focuses on high-throughput sequencing, bioinformatics, and synthetic biology to address challenges in human health, agriculture, and industrial biotechnology. The institute leads major national initiatives such as the MyGenom project, which aims to sequence 10,000 Malaysian genomes to establish a reference baseline for precision medicine. MGVI provides a wide range of services, including whole-genome sequencing, transcriptomics, and protein expression, to academic and industrial partners. By advancing genomic research and developing local expertise, MGVI plays a critical role in Malaysia's biotechnology ecosystem and bioeconomy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Malaysia Genome Institute.